CORRECTION

Correction: High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity

The *PLOS ONE* Staff

The following information is missing from the Competing Interests statement: Calciscon AG holds a patent for the T50-Test and markets the T50-Test. The publisher apologizes for this error. The complete, correct Competing Interests statement is: The authors have the following interests. This study was supported by an unrestricted grant from Fresenius MC, Bad Homburg, Germany. Bernard Canaud is employed by Fresenius MC and holds shares in this company. Andreas Pasch is a part-time employee of Calciscon and holds shares in this company. Mauro Dionisi and Matthias Meier are both employed by Calciscon. Calciscon AG holds a patent for the T50-Test and markets the T50-Test. There are no other patents, products in development or marketed products to declare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Reference

1. Dekker M, Pasch A, van der Sande F, Konings C, Bachtler M, Dionisi M, et al. (2016) High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. PLoS ONE 11(4): e0151508. doi: [10.1371/journal.pone.0151508](https://doi.org/10.1371/journal.pone.0151508) PMID: [27064679](https://pubmed.ncbi.nlm.nih.gov/27064679/)

OPEN ACCESS

Citation: The *PLOS ONE* Staff (2016) Correction: High-Flux Hemodialysis and High-Volume Hemodiafiltration Improve Serum Calcification Propensity. PLoS ONE 11(6): e0156923. doi:10.1371/journal.pone.0156923

Published: June 1, 2016

Copyright: © 2016 The PLOS ONE Staff. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.